Cargando…

Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area

BACKGROUND: Isoniazid (INH) prophylaxis (Px) has good efficacy for preventing tuberculosis (TB) in the general population. However, its use for the treatment of latent TB infections (LTBI) in liver transplant (LT) recipients is challenging because little is known about INH-induced hepatotoxicity in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moon, Hyung Hwan, Park, So Yeon, Kim, Jong Man, Park, Jae Berm, Kwon, Choon Hyuck David, Peck, Kyong Ran, Kim, Sung-Joo, Lee, Suk-Koo, Joh, Jae-Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248040/ https://www.ncbi.nlm.nih.gov/pubmed/28579606 http://dx.doi.org/10.12659/AOT.902989

Ejemplares similares

Cardiac tamponade caused by tuberculosis pericarditis in renal transplant recipients
por: Kim, Jong Man, et al.
Publicado: (2011)

A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis
por: Philipose, Jobin, et al.
Publicado: (2022)

Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital
por: Chung, Sung Jun, et al.
Publicado: (2020)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

Mycobacterium tuberculosis infections in cynomolgus monkey transplant recipients and institution of a screening program for the prevention and control of tuberculosis
por: Choi, Eun Wha, et al.
Publicado: (2016)

High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients
por: Kim, Jong Man, et al.
Publicado: (2014)

Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors
por: Lai, Edward Chia-Cheng, et al.
Publicado: (2021)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis
por: Torres, Martha, et al.
Publicado: (2015)

1694 Risk factors and outcomes of isoniazid hepatotoxicity in children with latent tuberculosis
por: Devrim, Ilker, et al.
Publicado: (2014)

Empiric vs screening‐based use of isoniazid for tuberculosis prophylaxis: Safety and effectiveness in lung transplant recipients in Saudi Arabia
por: Korayem, Ghazwa B., et al.
Publicado: (2020)

Publisher Correction: Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors
por: Lai, Edward Chia‑Cheng, et al.
Publicado: (2021)

Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
por: Sung, Yoon-Kyoung, et al.
Publicado: (2018)

Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2020)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis
por: Oscanoa, Teodoro J., et al.
Publicado: (2023)

Latent tuberculosis: Risk factors, screening and treatment in liver transplantation recipients from an endemic area
por: Lauar, Isabela Dias, et al.
Publicado: (2021)

Comparative evaluation of QuantiFERON-TB Gold Plus for diagnosis of latent tuberculosis infection during solid organ transplantation
por: Yoon, Sun Joo, et al.
Publicado: (2020)

Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV
por: Vojnov, Lara, et al.
Publicado: (2022)

Delphi Survey on the Current and Future Korean Guidelines for Isoniazid-Monoresistant Tuberculosis
por: Seo, Wan, et al.
Publicado: (2023)

Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database
por: Seo, Woo Jung, et al.
Publicado: (2023)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Does an Isoniazid Prophylaxis Register Improve Tuberculosis Contact Management in South African Children?
por: van Soelen, Nelda, et al.
Publicado: (2013)

Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia
por: Geremew, Demeke, et al.
Publicado: (2022)

Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients in Korea
por: Lee, Jee Hyun, et al.
Publicado: (2009)

Bile Duct Reconstruction by a Young Surgeon in Living Donor Liver Transplantation Using Right Liver Graft
por: Kim, Jong Man, et al.
Publicado: (2014)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active Mycobacterium tuberculosis Infections in Tertiary Care Setting?
por: Jung, Jaewan, et al.
Publicado: (2021)

Isoniazid-Resistant Tuberculosis, Taiwan, 2000–2010
por: Lai, Chih-Cheng, et al.
Publicado: (2011)

Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study
por: Denholm, Justin T, et al.
Publicado: (2014)

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
por: Ha, Lawrence, et al.
Publicado: (2017)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

790. The Efficacy of the Interferon-γ Releasing Assay-Based Isoniazid Treatment for Preventing Active Tuberculosis in Kidney Transplant Recipients: A Quasi-experimental Study
por: Kim, Hae-In, et al.
Publicado: (2018)

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis
por: Jung, Jin Ah, et al.
Publicado: (2015)

Evaluation of latent tuberculosis infection in liver transplant recipients
por: Ahmadinejad, Zahra, et al.
Publicado: (2021)

Serial ImmuKnow assay in stable kidney transplant recipients
por: Moon, Hyung Hwan, et al.
Publicado: (2014)

Protrusion of hepatocellular carcinoma is a predictor of early recurrence in hepatectomy patients after spontaneous rupture
por: Han, Seung Rim, et al.
Publicado: (2016)

Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study
por: Kwak, Se Hyun, et al.
Publicado: (2020)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_078lfi5gd4ftap683g8sg4j0jh